Safety and tolerability of adjunctive aripiprazole in major depressive disorder: A pooled post hoc analysis (studies CN138-139 and CN138-163)

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 11, Issue 6, 2009, Pages 344-352

  Nelson, J Craig ^a   Thase, Michael E ^b   Trivedi, Madhukar H ^c   Fava, Maurizio ^d   Han, Jian ^e   van Tran, Quynh ^f   Pikalov, Andrei ^f   Qi, Ying ^e   Carlson, Berit X ^e   Marcus, Ronald N ^e   Berman, Robert M ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; PROPRANOLOL; SERTRALINE; VENLAFAXINE;

ABNORMAL LABORATORY RESULT; ADJUVANT THERAPY; AGE; AKATHISIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ATTENTION DISTURBANCE; BLURRED VISION; BODY WEIGHT; CELLULITIS; CLINICAL TRIAL; CONSTIPATION; COORDINATION DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FATIGUE; FLATULENCE; HEMATOCHEZIA; HUMAN; HYPERHIDROSIS; INSOMNIA; LIBIDO DISORDER; MAJOR DEPRESSION; MOUTH PAIN; MUSCLE SPASM; NERVOUSNESS; PNEUMONIA; POST HOC ANALYSIS; PREDICTION; QT INTERVAL; RASH; RESTLESS LEGS SYNDROME; RESTLESSNESS; SEDATION; SIDE EFFECT; SOMNOLENCE; SORE THROAT; SUICIDAL IDEATION; THORAX PAIN; TREATMENT DURATION; URINARY HESITANCY; URINARY TRACT INFECTION; VITAL SIGN; WEIGHT GAIN;

EID: 77954138432     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.08m00744gre     Document Type: Article

References (30)

1. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006; 75(3):139-153.
2. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder (revision). Am J Psychiatry. 2000;157(suppl 4):1-45.
3. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853.
4. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165.
5. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381-389.
6. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400-1411.
7. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol. 2002;441(3):137-140.
8. Jordan S, Koprivica V, Dunn R, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004;483(1):45-53.
9. Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005;66(10): 1289-1297.
10. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology. 2006;31(11):2505-2513.
11. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224-236.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
13. Chandler GM, Iosifescu DV, Pollack MH, et al. Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2009 Sept 21 [Epub ahead of print]
14. Montgomery SA, Asberg MC. A new depression rating scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
15. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
16. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61(2-3):123-136.
17. Marcus RN, Carson WH, McQuade RD, et al. Overview of safety and tolerability of aripiprazole in acute mania. New research poster 796 presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
18. Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28(2):203-209.
19. Lane RM. SSRI-induced extrapyramidal side effects and akathisia: implications for treatment. J Psychopharmacol. 1998;12(2):192-214.
20. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998;32(6):692-698.
21. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160(9):1651-1658.
22. Keck PE Jr, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs. 2003;12(4):655-662.
23. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
24. Newcomer JW. Second-Generation (atypical) Antipsychotics and Metabolic Effects: a Comprehensive Literature Review. CNS Drugs. 2005;19(suppl 1):1-93.
25. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63(9):763-771.
26. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6(4): 325-337.
27. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebocontrolled 26-week study. J Clin Psychiatry. 2003;64(9):1048-1056.
28. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20(4): 536-546.
29. Vieta E, T'joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially non-responsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry. 2008;165(10):1316-1325.
30. Ketter TA, Wang PW, Chandler RA, et al. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann Clin Psychiatry. 2006;18(3): 169-172.